Retraction: Exploring novel fluorine-rich fuberidazole derivatives as hypoxic cancer inhibitors: Design, synthesis, pharmacokinetics, molecular docking, and DFT evaluations
The · 2026
Read Retraction: Exploring novel fluorine-rich fuberidazole derivatives as hypoxic cancer inhibitors: Design, synthesis, pharmacokinetics, molecular docking, and DFT evaluations by The (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13143096.txt.
Description
A retraction notice from 2026 withdraws a study that claimed to design fluorine-rich drug candidates against oxygen-starved cancers. The notice states that after publication, concerns were raised about the study's supporting file and its statistical analysis. Similar baseline patterns were found in spectra that were meant to show different compounds, a sign the data may not be trustworthy.
The notice also flags the statistics: the methods named a test suited to two groups, yet many experiments had more than two conditions. No p-values appeared in the results, tables, or figures. The retraction record preserves why the original claims can no longer be relied on. The notice names the affected supporting file directly.
Catalog record
| CREATOR | The |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 4 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |